Reflector

Can private sector serve public interests in battling rare diseases?

EU tasked with translating bold declarations into reality.

Must find common ground between digitalization and protection laws.

Must maintain trust in face of customary, non-pandemic challenges.

Universal strategy push elicits range of constituency views.

Pandemic sparks call for European manufacturing renaissance.

Industry prospects at mercy of public discourse, policy shifts.

Pandemic fallout could spell fundamental business and policy shifts.

With coronavirus a stark backdrop, European initiative pushes for “fair” drug prices to spur investment in pharma innovation.

Medical devices manufacturers and pharma companies alike should review their compliance strategies as the EU Medical Device Regulation Date of Application approaches.

The collection of source plasma for new therapies igniting debate.

New OECD study doesn’t shed much light on the effectiveness of managed entry agreements for drug access.

What to make of new momentum in advancing health agenda.

European Commission working group is looking closely at marketing obligations for centrally authorized products.

A formal effort is underway in Europe to gather concrete clues on the value of real-world evidence in payer decision-making.

Change in season ushers in a pivotal period for pharma in shaping the direction of EU healthcare.

As well as official European projections of sharply slowing industry growth and geopolitical concerns, pharma executives face additional hazards as they plot their medium-term strategies, writes Reflector.

Exploring the EU’s struggles and new efforts in promoting cell and gene drugs.

As the EU prepares for a change of governance, policymakers should take note of recent comments about the "poisoned atmosphere" surrounding healthcare policy debates, writes Reflector.

The Commission’s gestures toward enacting formal standards to digitize health records are masking wider policy gaps.

Parliament throws wrench in Commission’s plan to regulate HTA.

What will come out of Austria’s shakeup of European pharma rules?

A recently announced collaboration between EUnetHTA, WHO, and ISPOR brings home the fact that there is still no real agreement on a definition of HTA, writes Reflector.

Research-based companies in Europe look as though they have lost one battle on preserving incentives for innovation – but the bigger war is only now getting underway, writes Reflector.

European drug innovators ready their defense as the Commission mulls manufacturing waiver for generic competitors.

Figuring out the workings of the EU in topics related to health can be akin to deciphering Egyptian hieroglyphs, making it challenging for companies to plan ahead, writes Reflector.

Looking back at the agenda of a 1985 EFPIA conference demonstrates that, three decades on, the European drug industry is still seeking a pill for its own ills.

Looking back at the agenda of a 1985 EFPIA conference, Reflector sees that, three decades on, the European drug industry is still seeking a pill for its own ills.

Scope of supplementary protection certificate (SPC) could change.

In the coming weeks, the EU will decide if the degree of protection offered to drug firms by research incentives such as the SPC are really in the interests of patients and society. Reflector reports.